Analysis of long-term results of treatment of patients with breast cancer after neoadjuvant chemotherapy

Breast cancer is one of the leading causes of morbidity and mortality among women worldwide, which is an important problem of modern oncology. The latest approaches to the treatment of breast cancer are based on multicomponent therapeutic strategies, including neoadjuvant chemotherapy, which reduces tumour size, increases the chances of organ-preserving surgery and provides early assessment of tumour sensitivity to therapy. However, the analysis of the long-term outcomes of patients after neoadjuvant chemotherapy remains insufficiently covered in the scientific literature. This issue is of particular importance given the increasing availability of modern drugs and personalised approaches to breast cancer treatment. The aim of the study is to conduct a comprehensive assessment of the long-term treatment outcomes of patients with breast cancer who have undergone neoadjuvant chemotherapy, which required the use of certain research methods, namely bibliosemantic, medical and statistical analysis and the method of expert evaluation. The study of the effects of neoadjuvant chemotherapy is an important area of modern oncology. Thanks to this research, it is possible to develop more and more effective and safe methods of treating breast cancer, which allows improving the prognosis for patients and increasing their chances of recovery.

References

1. Sung H., Ferlay J., Siegel R.L. et al. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin., 71(3): 209–249. doi: 10.3322/caac.21660.
2. Kashyap D., Pal D., Sharma R. et al. (2022) Global increase in breast cancer incidence: Risk factors and preventive measures. BioMed Res. Int., 2022(1): 9605439.
3. Rafalska Y., Kosyachenko K. (2021) Marketing research of the medicine market for the treatment of breast cancer in Ukraine. Ukr. Sci. Med. Youth J., 4(127): 77–83.
4. Kim G., Bahl M. (2021) Assessing risk of breast cancer: A review of risk prediction models. J. Breast Imaging, 3(2): 144–155. doi: 10.1093/jbi/wbab001.
5. Houghton S.C., Hankinson S.E. (2021) Cancer progress and priorities: Breast cancer. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research. Cosponsored by the American Society of Preventive Oncology, 30(5): 822–844. doi: 10.1158/1055-9965.EPI-20-1193.
6. Yu J., Jiang S., Liu T. et al. (2024) Secondary risk-reducing strategies for contralateral breast cancer in BRCA1/2 variant carriers: A systematic review and meta-analysis. Advances in Therapy. doi: 10.1007/s12325-024-03054-x.
7. Howard F.M., Olopade O.I. (2021) Epidemiology of triple-negative breast cancer: A review: A review. Cancer Journal (Sudbury, Mass.), 27(1): 8–16. doi: 10.1097/PPO.0000000000000500.
8. Fernandes Dantas Filho F., Vanti Beretta M., Borba Brum M.C., da Costa Rodrigues T. (2023) Association between fixed night work and obesity: a systematic literature review. Clinical and Biomedical Research, 42(4). seer.ufrgs.br/index.php/hcpa/article/view/123719.
9. Bhushan A., Gonsalves A., Menon J.U. (2021) Current state of breast cancer diagnosis, treatment, and theranostics. Pharmaceutics, 13(5): 723.
10. Orrantia-Borunda E., Anchondo-Nuñez P., Acuña-Aguilar L.E. et al. (2022) Subtypes of Breast Cancer. In Breast Cancer (pp. 31–42). Exon Publications. doi.org/10.36255/exon-publications-breast-cancer-subtypes.
11. Johnson K.S., Conant E.F., Soo M.S. (2021) Molecular subtypes of breast cancer: A review for breast radiologists. J. Breast Imaging, 3(1): 12–24. doi: 10.1093/jbi/wbaa110.
12. Szymiczek A., Lone A., Akbari M.R. (2021) Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review. Clinical Genetics, 99(5): 613–637.
13. Ensenyat-Mendez M., Llinàs-Arias P., Orozco J.I.J. et al. (2021) Current triple-negative breast cancer subtypes: Dissecting the most aggressive form of breast cancer. Frontiers in Oncology, 11: 681476. doi: 10.3389/fonc.2021.681476.
14. Tsang J.Y.S., Tse G.M. (2020) Molecular classification of breast cancer. Advances in Anatomic Pathology, 27(1): 27–35. doi: 10.1097/PAP.0000000000000232.
15. Hu C., Polley E.C., Yadav S. et al. (2020) The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort. J. National Cancer Institute, 112(12): 1231–1241. doi: 10.1093/jnci/djaa023.
16. Ginsburg O., Yip C.-H., Brooks A. et al. (2020) Breast cancer early detection: A phased approach to implementation. Cancer, 126 Suppl. 10(S10): 2379–2393.
17. Marini T.J., Castaneda B., Iyer R. et al. (2023) Breast ultrasound volume sweep imaging: A new horizon in expanding imaging access for breast cancer detection. J. Ultrasound Med., 42(4): 817–832. doi: 10.1002/jum.16047.
18. Ab Mumin N., Ramli Hamid M.T., Wong J.H.D. et al. (2022) Magnetic resonance imaging phenotypes of breast cancer molecular subtypes: A systematic review. Academic Radiology, 29 Suppl. 1: S89–S106. doi: 10.1016/j.acra.2021.07.017.
19. Fornage B.D., Fornage B.D. (2020) Core-needle biopsy. In: B.D. Fornage (Ed.), Interventional ultrasound of the breast: From biopsy to ablation (pp. 253–316). Springer Int. Pub.
20. Yoshida R. (2021) Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer (Tokyo, Japan), 28(6), 1167–1180. doi: 10.1007/s12282-020-01148-2.
21. Tay T.K.Y., Tan P.H. (2021) Liquid biopsy in breast cancer: A focused review. Arch. Pathol. Lab. Med., 145(6): 678–686. doi: 10.5858/arpa.2019-0559-RA.
22. Alimirzaie S., Bagherzadeh M., Akbari M.R. (2019) Liquid biopsy in breast cancer: A comprehensive review. Clinical Genetics, 95(6): 643–660. doi: 10.1111/cge.13514.
23. He Z., Chen Z., Tan M. et al. (2020) A review on methods for diagnosis of breast cancer cells and tissues. Cell Proliferation, 53(7): e12822. doi: 10.1111/cpr.12822.
24. Riis M. (2020) Modern surgical treatment of breast cancer. Annals of Medicine and Surgery 2012(56): 95–107. doi: 10.1016/j.amsu.2020.06.016.
25. Chirilă M.-E., Kraja F., Marta G.N. et al. (2024) Organ-sparing techniques and dose-volume constrains used in breast cancer radiation therapy — Results from European and Latin American surveys. Clinical and Translational Radiation Oncology, 46(100752): 100752.
26. Asaoka M., Gandhi S., Ishikawa T., Takabe, K. (2020). Neoadjuvant chemotherapy for breast cancer: Past, present, and future. Breast Cancer: Basic and Clinical Research, 14: 1178223420980377. doi: 10.1177/1178223420980377.
27. Peddie N., Agnew S., Crawford M. et al. (2021). The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis. Breast (Edinburgh, Scotland), 58: 147–159. doi: 10.1016/j.breast.2021.05.005.
28. Korde L.A., Somerfield M.R., Hershman D.L., Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer Guideline Expert Panel (2022) Use of immune checkpoint inhibitor pembrolizumab in the treatment of high-risk, early-stage triple-negative breast cancer: ASCO guideline rapid recommendation update. J. Clin. Oncol., 40(15): 1696–1698. doi: 10.1200/JCO.22.00503.
29. Barzaman K., Moradi-Kalbolandi S., Hosseinzadeh A. et al. (2021) Breast cancer immunotherapy: Current and novel approaches. International Immunopharmacology, 98(107886): 107886. doi: 10.1016/j.intimp.2021.107886.
30. Shah C., Bauer-Nilsen K., McNulty R.H., Vicini F. (2020) Novel radiation therapy approaches for breast cancer treatment. Seminars in Oncology, 47(4): 209–216.
31. Tsai H.-T., Huang C.-S., Tu C.-C. et al. (2020) Multi-gene signature of microcalcification and risk prediction among Taiwanese breast cancer. Sci. Rep., 10(1): 18276.
32. Tong L., Mitchel J., Chatlin K., Wang M.D. (2020) Deep learning based feature-level integration of multi-omics data for breast cancer patients survival analysis. BMC Medical Informatics and Decision Making, 20(1): 225. doi: 10.1186/s12911-020-01225-8.
33. Smith I., Robertson J., Kilburn L. et al. (2020) Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. The Lancet Oncology, 21(11): 1443–1454.
34. Jung H., Lu M., Quan M.L. et al. (2022) New method for determining breast cancer recurrence-free survival using routinely collected real-world health data. BMC Cancer, 22(1): 281. doi: 10.1186/s12885-022-09333-6.
35. Romeo V., Accardo G., Perillo T. et al. (2021) Assessment and prediction of response to neoadjuvant chemotherapy in breast cancer: A comparison of imaging modalities and future perspectives. Cancers, 13(14): 3521. doi: 10.3390/cancers13143521.
36. Gampenrieder S.P., Rinnerthaler G., Greil R. (2013) Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future. J. Oncol., 732047.
37. Van Baelen K., Geukens T., Maetens M. et al. (2022) Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Annals of Oncology, 33(8): 769–785. doi: 10.1016/j.annonc.2022.05.006.
38. Pesotsky R.S.P., Semiglazov V.F.S., Krivorotko P.V.K. et al. (2023) Evaluation of long-term results of treatment of patients with residual tumors (including those with minimal forms of ypT1abN0), with pathomorphological complete response (pCR) after neoadjuvant systemic therapy, with primary minimal breast cancer (pT1abN0M0). Pharmateca, 6–7: 59–67. doi.org/10.18565/pharmateca.2023.6-7.59-67.
39. Guarino A., Polini C., Forte G. et al. (2020) The effectiveness of psychological treatments in women with breast cancer: A systematic review and meta-analysis. J. Clin. Med., 9(1): 209.
40. Kwon Y. (2021) Possible beneficial effects of N-acetylcysteine for treatment of triple-negative breast cancer. Antioxidants (Basel, Switzerland), 10(2): 169.
41. Schmid P., Cortes J., Dent R. et al. (2024) Overall survival with pembrolizumab in early-stage triple-negative breast cancer. New Engl. J. Med., 391(21): 1981–1991.
42. Mokhtari-Hessari P., Montazeri A. (2020) Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018. Health and Quality of Life Outcomes, 18(1): 338. doi: 10.1186/s12955-020-01591-x.
43. Franzoi M.A., Agostinetto E., Perachino M. et al. (2021) Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. The Lancet Oncology, 22(7): e303–e313. doi: 10.1016/S1470-2045(20)30666-5.
44. Li J., Guan X., Fan Z. et al. (2020) Non-invasive biomarkers for early detection of breast cancer. Cancers, 12(10): 2767. doi: 10.3390/cancers12102767.
45. Ambrosone C.B., Zirpoli G.R., Hutson A.D. et al. (2020) Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221). J. Clin. Oncol., 38(8): 804–814.
46. Al-Masri M., Aljalabneh B., Al-Najjar H., Al-Shamaileh T. (2021) Effect of time to breast cancer surgery after neoadjuvant chemotherapy on survival outcomes. Breast Cancer Research and Treatment, 186(1): 7–13. doi: 10.1007/s10549-020-06090-7.
47. Hatschek T., Foukakis T., Bjöhle J. et al. (2021) Neoadjuvant trastuzumab, pertuzumab, and docetaxel vs trastuzumab emtansine in patients with ERBB2-positive breast cancer: A phase 2 randomized clinical trial. JAMA Oncol., 7(9): 1360–1367.
48. Zhang L., Wu Z.-Y., Li J. et al. (2022) Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial. Int. J. Cancer, 150(4): 654–662.
49. Kravtsova E., Tsyganov M., Tsydenova I. et al. (2024) Markers of predicting response to neoadjuvant chemotherapy in breast cancer: New in molecular oncology. Asian Pacific Journal of Cancer Prevention: APJCP, 25(11): 3761–3769.
50. Liao Q., Deng D., Xie Q. et al. (2022) Clinical characteristics, pregnancy outcomes and ovarian function of pregnancy-associated breast cancer patients: a retrospective age-matched study. BMC Cancer, 22(1): 152. doi: 10.1186/s12885-022-09260-6.
51. Montagna G., Gupta H.V., Hannum M. et al. (2021) Intraoperative opioids are associated with improved recurrence-free survival in triple-negative breast cancer. Br. J. Anaesth., 126(2): 367–376. doi: 10.1016/j.bja.2020.10.021.
52. Britt K.L., Cuzick J., Phillips K.-A. (2020) Key steps for effective breast cancer prevention. Nature Reviews. Cancer, 20(8): 417–436. doi: 10.1038/s41568-020-0266-x.
53. Eckert K.M., Hoskin T.L., Olson C.A. et al. (2024) In-breast tumor progression during neoadjuvant chemotherapy: Impact on and factors influencing distant recurrence-free survival. Annals of Surg. Oncol., 31(13): 8856–8865. doi: 10.1245/s10434-024-16178-9.
54. Hanson S.E., Lei X., Roubaud M.S. et al. (2022) Long-term quality of life in patients with breast cancer after breast conservation vs mastectomy and reconstruction. JAMA Surg., 157(6): e220631. doi: 10.1001/jamasurg.2022.0631.
55. Konieczny M., Cipora E., Sygit K., Fal A. (2020) Quality of life of women with breast cancer and Socio-demographic factors. APJCP, 21(1): 185–193. doi: 10.31557/APJCP.2020.21.1.185.
56. Haver H. L., Ambinder E. B., Bahl M. et al. (2023). Appropriateness of breast cancer prevention and screening recommendations provided by ChatGPT. Radiology, 307(4): e230424. doi: 10.1148/radiol.230424.
57. Carreira H., Williams R., Dempsey H. et al. (2021) Quality of life and mental health in breast cancer survivors compared with non-cancer controls: a study of patient-reported outcomes in the United Kingdom. J. Cancer Survivorship: Research and Practice, 15(4): 564–575.
58. Ośmiałowska E., Misiąg W., Chabowski M., Jankowska-Polańska B. (2021) Coping strategies, pain, and quality of life in patients with breast cancer. J. Clin. Med., 10(19): 4469.
59. Heins M.J., de Ligt K.M., Verloop J. et al. (2022) Adverse health effects after breast cancer up to 14 years after diagnosis. Breast (Edinburgh, Scotland), 61: 22–28.
60. Elimimian E.B., Elson L., Li H. et al. (2021) Male breast cancer: A comparative analysis from the national cancer database. World J. Men’s Health, 39(3): 506–515.
61. Salas M., Mordin M., Castro C. et al. (2022) Health-related quality of life in women with breast cancer: a review of measures. BMC Cancer, 22(1): 66.
62. Thorat M.A., Balasubramanian R. (2020) Breast cancer prevention in high-risk women. Best Practice & Research. Clinical Obstetrics & Gynaecology, 65: 18–31.
63. van Dooijeweert C., Flach R.N., Ter Hoeve N.D. et al. (2024) Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial. Nature Cancer, 5(8): 1195–1205. doi: 10.1038/s43018-024-00788-z.
64. Kerr A.J., Dodwell D., McGale P. et al. (2022) Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer Treatment Rev., 105(102375): 102375. doi: 10.1016/j.ctrv.2022.102375.